Skip to content

Ustekinumab

Stelara (ustekinumab) is an antibody pharmaceutical. Ustekinumab was first approved as Stelara on 2009-01-15. It is used to treat crohn disease and psoriatic arthritis in the USA. It has been approved in Europe to treat crohn disease, psoriasis, and psoriatic arthritis. The pharmaceutical is active against interleukin-12 subunit beta.
Trade Name Stelara
Common Name Ustekinumab
ChEMBL ID CHEMBL1201835
Indication crohn disease, psoriasis, psoriatic arthritis
Drug Class Monoclonal antibodies: interleukins as targets|monoclonal antibodies: fully human, neural indications
Ustekinumab
Get full access now